 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
174 News |  |
| 123» |
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Review, Journal: Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. (Pubmed Central) - Mar 30, 2022
These secondary analyses and real-world data complement the primary results with nebulized GLY from Phase III studies and support the need for the inclusion of patients representative of real-world clinical practice in RCTs. In addition, these data suggest that RCTs for COPD therapies should be complemented with real-world observational studies.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal: An ultrasensitive LC-MS/MS method and application to clinical dose-range finding for glycopyrrolate via an e-Nebulizer. (Pubmed Central) - Nov 21, 2021
Pharmacokinetic analysis showed good dose proportionality over the studied dose range, where C was found to be Y = 1.354*X + 1.968 (r = 0.9984), and AUC was Y = 4.661*X + 23.32 (r = 0.9976). The study clearly demonstrated the importance of an ultrasensitive (500 fg/ml LLOQ) method.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal, HEOR, Real-world evidence: Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with glycopyrrolate/eFlow® in the US: A real-world data analysis. (Pubmed Central) - Oct 1, 2021
The study clearly demonstrated the importance of an ultrasensitive (500 fg/ml LLOQ) method. Among patients initiating GLY in a real-world setting, COPD medications, hospitalizations, other HRU, and exacerbations decreased after treatment initiation compared with the 6-month pre-index period.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Lot of learning and sharing in these two days. Thanks to all the participants in the course. So much gratitude from the entire team. The course is built on decades of EP 101 experience from the masters Dr. Estes and Dr. Cooper @narrowQRS (Twitter) - Aug 22, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal: Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. (Pubmed Central) - Jul 29, 2021
Significant improvements in EXACT-RS total scores were observed only in the CB group. Together, these results support the use of GLY 25 μg BID in patients with COPD, regardless of their CB status.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal: Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD. (Pubmed Central) - Jul 29, 2021
A simple comorbidity count demonstrated that a majority of patients with COPD in the GOLDEN 3 and 4 studies had multiple comorbidities, with CVD being common in those with high comorbidity count. Results from this post hoc analysis demonstrate that GLY improved FEV and SGRQ scores in individuals with COPD, independent of their comorbidities or CVD status.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal: Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD. (Pubmed Central) - Jul 8, 2021
P4
Nebulized GLY resulted in marked improvements in RV up to 6 h post-treatment, compared with placebo. Improvements were also observed with GLY in spirometric and plethysmographic parameters of lung function.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal: The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies. (Pubmed Central) - Jun 30, 2021
Treatment with nebulized GLY improved lung function and symptom scores, regardless of baseline rescue medication use. These results support the use of nebulized GLY for the treatment of COPD, independent of baseline rescue medication use.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal, Patient reported outcomes: Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. (Pubmed Central) - Jun 30, 2021
These data support the efficacy and safety of GLY 25 µg BID in patients with moderate-to-very-severe COPD, independent of gender. Gender similarities in airflow improvement and differences in symptom-reporting augment the evidence supporting the consideration of individualized treatment plans for COPD patients.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal, Real-world evidence: Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow CS. (Pubmed Central) - Jun 30, 2021
Over 80% of participants said they "probably"/"definitely" would continue to use eFlow. Based on this real-world study, the majority of patients were highly satisfied with, and confident in, using eFlow.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Journal, Patient reported outcomes: Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. (Pubmed Central) - Jun 30, 2021
GLY 25 µg BID resulted in numerical improvements in FEV, SGRQ total scores and SGRQ responder rates in patients with moderate-to-very-severe COPD, regardless of A/D status at baseline; significant improvements were noted only in the A/D (+) group. The results emphasize the importance of considering underlying comorbidities including A/D when evaluating the efficacy of COPD treatments.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical, Retrospective data, Journal: Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies. (Pubmed Central) - Jun 24, 2021
P3
Using a composite endpoint, pooled data from two 12-week Phase III placebo-controlled trials (GOLDEN 3, NCT02347761; GOLDEN 4, NCT02347774) were analyzed to determine whether glycopyrrolate inhalation solution (25 mcg and 50 mcg) administered twice daily (BID) via the eFlow Closed System nebulizer (GLY) reduced the risk of clinically important deterioration (CID) in patients with moderate-to-very-severe COPD...Subjects <65 years (OR 0.45 [0.29-0.68]) and those with PIFR <60 L/min (OR 0.36 [0.20-0.67]) exhibited the largest benefit. Nebulized GLY over 12 weeks significantly reduced the risk of CID and provided greater short-term stability in patients with moderate-to-very-severe COPD.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Dear Dr JM Cooper, I'm an EP fellow from Vietnam. I would like to join the EP101 course. How can I register for those interesting lectures? Thank you. (Twitter) - Jun 10, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Brazil would be excited and honored to welcome EP 101! But thanks for this inclusive virtual format! Great talks and a very didatic course! (Twitter) - Jun 7, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you so much to all the attendees for our #EP101 course this past weekend! Over 70 different countries, almost 900 registrants! While nobody would ever wish for a pandemic, one of the beautiful things that has emerged from Covid is enhanced teaching access world-wide! (Twitter) - Jun 7, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
I'm so grateful you decided to use the virtual platform! I'm not sure, I' been able to travel to 🇺🇲 or given a seat as a non-US, and 🇩🇰 being a small country, we don't have an EP101 like this. I'm finishing my PhD hoping for a future in EP and I'm deeply grateful for this weekend (Twitter) - Jun 7, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Certainly this lecture from @MRobinsonEP was key for both basics and pro tips regarding diagnosis and ablation of AVNRT! Can’t get enough of #EP101 #EPeeps @narrowQRS @BSCCardiology (Twitter) - Jun 7, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Day 1 of #EP101 by @narrowQRS and @BSCCardiology was brillant! Loved the tree/forest analogy & the intro to ep signals/caths by @Zo_EP2 and the amazing diagrams by Dr. Sam Asirvatham! Alas couldn't tune into Day 2. Definitely recommend to all as it's an excellent course! #EPeeps (Twitter) - Jun 7, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you so very much for the great feedback! It was indeed a very successful virtual #EP101!! Many thanks to the amazing faculty @Zo_EP2 @KrishKancharla @Ed_Gerst @DrBradleyKnight @MRobinsonEP @OutOfRhythm @DrGregMichaud @SilviaPriori1 #SamAsirvatham #SonnyJackman #MarkEstes (Twitter) - Jun 6, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you for your interesting presentation. It is possible to receive all Presentations of EP 101 Programs in 2021 as Online Film on BSc Website or PDF receive? (Twitter) - Jun 6, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Great weekend learning #EP101 with my #EPup. Thank you, Drs Estes and @narrowQRS for a great course. Looking forward to #Device101 (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Final lecture of #EP101: Management of VT in ICM/NICM by Dr. #ConorBarrett; Key trials on primary prevention of SCD in CM with a recent trial on RF utilization for VT noted below 👇 @narrowQRS @BSCCardiology #EPeeps (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Excellent session! #EP101 summarizing the major trials investigating the use of prophylactic AAD for the prevention of #ablateVT #EPeeps @narrowQRS @OutOfRhythm @BSCCardiology (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Amazing lecture on AVNRT with from Dr. @MRobinsonEP. Pro tips (and more below!) from Dr. R: pace from proposed ablation site for AVNRT --> 1) verify A/V capture, 2) stability of site with passive/pacing capture, 3) ablate in SR. #EP101 #EPeeps @BSCCardiology @narrowQRS (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Part 2: Ablation of AT by #DrJackman; fundamental to understand how catheters (bipolar v. unipolar) "see" the signals -> enables understand of "where/when" a signal is occurring. This leads to the 🔑to earliest activation/ideal ablation. #EP101 #EPeeps @narrowQRS @BSCCardiology (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Successful ablation for atrial tachy: site of earliest activation #EP101 #EPeeps @BSCCardiology @narrowQRS (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Part 1 of #DrJackman's lectures (so amazing!): Ablation of accessory pathways; Important to recognize the oblique course of pathway; "V1 is best for differentiating ventricular insertion." --- Surface ECG only shows ventricular insertion #EPeeps #EP101 @narrowQRS @BSCCardiology (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Really interesting talk about accessory pathway ablation by Jackman #EPeeps #EP101 @BSCCardiology @narrowQRS (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Dr. @SilviaPriori1 discussing the Role of Genetic Testing in EP; a very important discussion! Elucidation of disease genotype when imaging may not provide the most clear information of phenotype leading improved risk/decision making #EPeeps #EP101 @narrowQRS @BSCCardiology (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Day 2! #EP101 @BSCCardiology @narrowQRS #DrEstes (Twitter) - Jun 6, 2021
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: @DrGregMichaud discussing AF Ablation. Clear examples by Dr. Michaud regarding appropriate endpoints/isolation EGMs along with "ideal" RF settings. Most important: risk reduction! Patient safety 🥇 #EP101 #EPeeps @narrowQRS @BSCCardiology (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Wonderful overview of managing ventricular arrhythmias in structural heart disease by #ConnorBarrett #EP101 (Twitter) - Jun 6, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: . @MRobinsonEP simultaneously breaking down AVNRT and also further debunking the common misunderstanding that patients with sudden palpitations must be having "panic attacks." #CorrectDiagnosis #EP101 (Twitter) - Jun 6, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
What a privilege and honor to participate in this great program with such impactful educators!! #EP101 #SylviaPriori #SonnyJackman #MarkEstes (Twitter) - Jun 6, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
This was one of the most important talks I've ever heard in my career. Practicing EP without a functional knowledge of cardiac genetics would be incomplete. #EP101 (Twitter) - Jun 6, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Mechanics of ablation by @Ed_Gerst. Important to understand physiology behind effective energy delivery into tissue for the more used RF. Different variables (tools) for lesion formation! #EP101 #EPeeps (Twitter) - Jun 5, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
#EP101 touching on more advanced therapies such as SBRT for #ablateVT #EPeeps @narrowQRS @Ed_Gerst @BSCCardiology (Twitter) - Jun 5, 2021
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: "Differentiating SVTs is by deductive reasoning." Another enjoyable aspect to EP--acting like Sherlock Holmes to understand and treat our patients! The clues are right in front of us 🧐 @DrBradleyKnight @narrowQRS @BSCCardiology #EP101 #EPeeps (Twitter) - Jun 5, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
EP with a view 🤓 #EP101 w/ @narrowQRS #DrMarkEstes (Twitter) - Jun 5, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
"How to read multi-channel EGM recordings." The basics of orientation make the biggest difference! Other important factors--channel color, grouping, and clipping @narrowQRS @BSCCardiology #EP101 #EPeeps (Twitter) - Jun 5, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
“The forest and the trees.” Big and small telling the story of the heart. @Zo_EP2 @BSCCardiology @narrowQRS #EP101 #Epeeps (Twitter) - Jun 5, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Dr. Sam Asirvatham going to town on his virtual whiteboard, dropping some knowledge about SVT maneuvers! #EP101 (Twitter) - Jun 5, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Fabulous lecture as always by @Ed_Gerst on day #1 of #EP101 !! (Twitter) - Jun 5, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Join course directors Dr. Mark Estes & @narrowQRS along with faculty @ed_gerst, @krishkancharla, @bradleyknight, @drgregmichaud, @mrobinsonep, @zo_ep2, Dr. Asirvatham, @SilviaPriori1, Dr. Barrett & Dr. Jackman for #EP101: https://t.co/3za26vD6jQ (Twitter) - Jun 3, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Just registered for #EP101! Looking forward to a weekend of learning about EP, starting to build a foundation for EP fellowship and hopefully connect with other #womeninEP! @narrowQRS @docwhitman @pravinp8 @anjalivaidyaMD @bostonsci ❤️⚡️ (Twitter) - May 31, 2021
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
And many many thanks to @edwardparadise for transporting me to & from Boston for that very special #EP101 in 2019. A trip to remember (including a memorable stop for pizza along the way - one of the first times I was allowed to eat food from a restaurant post-transplant) (Twitter) - May 31, 2021
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
...so that was the last time we had #EP101 in person. Scrambled last year to put together a virtual version, and pulled it off! This year's virtual EP101 will be awesome, and next year's back-in-person #EP101 will be a triumphant homecoming! 🎉 (Twitter) - May 31, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
😭That EP101 was particularly special, being right after the 100-day mark after my bone marrow transplant (in fact we specifically timed my BMT a bit earlier than initially planned, to maximize the chance of me being able to attend!) Extra special in hindsight, given covid 2020. (Twitter) - May 31, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
The beauty of a virtual platform this year for #EP101 is broad inclusivity! While the conference is designed for incoming EP Fellows, EP lab staff & Allied Health Professionals can register under "fellow" & select subcategory of "other" & enter your role/status 👍 More = merrier (Twitter) - May 28, 2021
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Designed for #EPfellows, #EP101 covers the fundamentals of electrophysiology including ablation of AV node reentry, how to read multi-channel recordings, differentiating SVTs and more with directors Dr. Mark Estes & @narrowQRS. Register: https://t.co/ME0BiKD1Jb #EPeeps (Twitter) - May 25, 2021